tetano
Editor, Senior Moderator
Clin Exp Med
. 2023 Oct 28.
doi: 10.1007/s10238-023-01223-w. Online ahead of print. Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Danilo De Novellis[SUP] #[/SUP][SUP] 1 2 [/SUP], Veronica Folliero[SUP] #[/SUP][SUP] 1 3 [/SUP], Valentina Giudice[SUP] #[/SUP][SUP] 1 2 [/SUP], Luca Pezzullo[SUP] 2 [/SUP], Giuseppina Sanna[SUP] 4 [/SUP], Raffaele Fontana[SUP] 2 [/SUP], Roberto Guariglia[SUP] 2 [/SUP], Carla Zannella[SUP] 5 [/SUP], Laura Mettivier[SUP] 2 [/SUP], Idalucia Ferrara[SUP] 2 [/SUP], Giovanni Boccia[SUP] 1 [/SUP], Maria Teresa Buonanno[SUP] 2 [/SUP], Maria Carmen Martorelli[SUP] 2 [/SUP], Serena Luponio[SUP] 2 [/SUP], Andrea Crudele[SUP] 1 [/SUP], Pasquale Pagliano[SUP] 1 [/SUP], Anna Maria Sessa[SUP] 2 [/SUP], Francesca Velino[SUP] 2 [/SUP], Maddalena Langella[SUP] 2 [/SUP], Aldo Manzin[SUP] 4 [/SUP], Massimiliano Galdiero[SUP] 5 [/SUP], Carmine Selleri[SUP] 6 7 [/SUP], Gianluigi Franci[SUP] 8 9 [/SUP], Bianca Serio[SUP] 10 11 [/SUP]
Affiliations
SARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19 due to immunosuppression. Anti-SARS-CoV-2 neutralizing antibodies protect against severe COVID-19. This retrospective real-life study aimed to evaluate seropositivity and neutralizing antibody rates against SARS-CoV-2 and its Omicron BA.1 variant in hematological patients. A total of 106 patients with different hematologic malignancies, who have mostly received three or more vaccine doses (73%), were included in this study. Serum was collected between May and June 2022. The primary endpoint was anti-SARS-CoV-2 antibody response against ancestral (wild type; wt) and Omicron BA.1 virus, defined as a neutralizing antibody titer ≥ 1:10. Adequate neutralizing antibody response was observed in 75 (71%) and 87 (82%) of patients for wt and Omicron BA.1 variants, respectively.However, patients with B-cell lymphoproliferative disorders and/or those treated with anti-CD20 monoclonal antibodies in the prior 12 months showed a lower seropositivity rate compared to other patients against both Omicron BA.1 variant (73% vs 91%; P = 0.02) and wt virus (64% vs 78%; P = 0.16). Our real-life experience confirmed that full vaccination against SARS-CoV-2 induces adequate neutralizing antibody protection for both the wt virus and Omicron BA.1 variants, even in hematological frail patients. However, protective measures should be maintained in hematological patients, especially those with B-cell lymphoproliferative diseases treated with anti-CD20 monoclonal antibodies, because these subjects could have a reduced neutralizing antibody production.
Keywords: COVID-19; Hematological malignancies; Immunity; Neutralizing antibodies; SARS-CoV-2.
. 2023 Oct 28.
doi: 10.1007/s10238-023-01223-w. Online ahead of print. Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Danilo De Novellis[SUP] #[/SUP][SUP] 1 2 [/SUP], Veronica Folliero[SUP] #[/SUP][SUP] 1 3 [/SUP], Valentina Giudice[SUP] #[/SUP][SUP] 1 2 [/SUP], Luca Pezzullo[SUP] 2 [/SUP], Giuseppina Sanna[SUP] 4 [/SUP], Raffaele Fontana[SUP] 2 [/SUP], Roberto Guariglia[SUP] 2 [/SUP], Carla Zannella[SUP] 5 [/SUP], Laura Mettivier[SUP] 2 [/SUP], Idalucia Ferrara[SUP] 2 [/SUP], Giovanni Boccia[SUP] 1 [/SUP], Maria Teresa Buonanno[SUP] 2 [/SUP], Maria Carmen Martorelli[SUP] 2 [/SUP], Serena Luponio[SUP] 2 [/SUP], Andrea Crudele[SUP] 1 [/SUP], Pasquale Pagliano[SUP] 1 [/SUP], Anna Maria Sessa[SUP] 2 [/SUP], Francesca Velino[SUP] 2 [/SUP], Maddalena Langella[SUP] 2 [/SUP], Aldo Manzin[SUP] 4 [/SUP], Massimiliano Galdiero[SUP] 5 [/SUP], Carmine Selleri[SUP] 6 7 [/SUP], Gianluigi Franci[SUP] 8 9 [/SUP], Bianca Serio[SUP] 10 11 [/SUP]
Affiliations
- PMID: 37898572
- DOI: 10.1007/s10238-023-01223-w
SARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19 due to immunosuppression. Anti-SARS-CoV-2 neutralizing antibodies protect against severe COVID-19. This retrospective real-life study aimed to evaluate seropositivity and neutralizing antibody rates against SARS-CoV-2 and its Omicron BA.1 variant in hematological patients. A total of 106 patients with different hematologic malignancies, who have mostly received three or more vaccine doses (73%), were included in this study. Serum was collected between May and June 2022. The primary endpoint was anti-SARS-CoV-2 antibody response against ancestral (wild type; wt) and Omicron BA.1 virus, defined as a neutralizing antibody titer ≥ 1:10. Adequate neutralizing antibody response was observed in 75 (71%) and 87 (82%) of patients for wt and Omicron BA.1 variants, respectively.However, patients with B-cell lymphoproliferative disorders and/or those treated with anti-CD20 monoclonal antibodies in the prior 12 months showed a lower seropositivity rate compared to other patients against both Omicron BA.1 variant (73% vs 91%; P = 0.02) and wt virus (64% vs 78%; P = 0.16). Our real-life experience confirmed that full vaccination against SARS-CoV-2 induces adequate neutralizing antibody protection for both the wt virus and Omicron BA.1 variants, even in hematological frail patients. However, protective measures should be maintained in hematological patients, especially those with B-cell lymphoproliferative diseases treated with anti-CD20 monoclonal antibodies, because these subjects could have a reduced neutralizing antibody production.
Keywords: COVID-19; Hematological malignancies; Immunity; Neutralizing antibodies; SARS-CoV-2.